The thesis
The drug supply chain will be won by whoever owns the chokepoints.
GLP-1 fill-finish, elastomer stoppers, bioprocessing resins, API reshoring, sterile injectables. Pharma Bottlenecks maps the manufacturing chain behind every blockbuster — not the molecules, the plants — and the listed companies that own each choke. Own the strait, not the tanker.
The market stares at the obvious names. The binding constraints sit further upstream, where a handful of companies own each physical chokepoint — and most of them are not household names. That is exactly the point.
We walk the supply chain layer by layer. For each link we ask the same three questions: who physically owns the choke, what it would take for someone else to credibly compete, and what the next catalyst is that forces the market to reprice.
The answers land on a living map of 45 listed companies across 10 chokepoints — each with a conviction tier, a bull and bear case, a catalyst path, and the source trail behind every mapping. It is a research map, not a portfolio. Own the strait, not the tanker.
The chokepoints
- ISterile fill-finish capacity
GLP-1 demand turned aseptic fill-finish lines into the scarcest asset in pharma; capacity books out years ahead.
- IIStoppers, syringes & drug-contact components
Every injectable passes through elastomer stoppers and glass barrels from two or three qualified suppliers — West's near-monopoly is the textbook choke.
- IIIPharmaceutical glass & vials
Borosilicate vial and cartridge capacity concentrates in three companies; every injectable ramp strains it.
- IVBioprocessing consumables & resins
Biologics manufacturing runs on single-use bags, filters and protein-A resin from an oligopoly with razor-blade economics.
- VAPI & small-molecule reshoring
Most US generic APIs route through China and India; BIOSECURE-era reshoring is funded, dated, and capacity-constrained.
- VICDMO capacity & the China exodus
WuXi handles a huge share of Western pipelines; every BIOSECURE headline reprices the non-Chinese CDMO bench.
- VIIPeptide & oligonucleotide manufacturing
GLP-1s are peptides and the new genetic medicines are oligos — both need specialized synthesis capacity that is genuinely scarce.
- VIIISterile injectables & shortage economics
Chronic shortages in generic sterile injectables are a structural underinvestment story with FDA shortage lists as the public catalyst tape.
- IXAnalytical instruments & QC release
Every batch released passes through chromatography, mass spec and sterility testing from a small instrument oligopoly.
- XPrivate giants & exposure vehicles
Catalent-under-Novo, Samsung Biologics, PolyPeptide, SHL — the manufacturing cap tables without US tickers, and the listed paths in.